Proceedings of the 2010 World Molecular Imaging Congress, Kyoto, Japan, September 8-11, 2010

Proceedings of the 2010 World Molecular Imaging Congress, Kyoto, Japan, September 8-11, 2010 Proceedings of the 2010 World Molecular Imaging Congress S500 B Academy of Molecular Imaging and Society for Molecular Imaging, 2010 Mol Imaging Biol (2010) 12 (Suppl 2):S509900YS1636 DOI: 10.1007/s11307-010-0453-3 Proceedings of the 2010 World Molecular Imaging Congress S501 Presentation Number 0002 Educational Workshop 2: Animal Imaging in Translational Medicine Animal Imaging in Drug Discovery and Development 1 2 3 2 1 Raymond E. Gibson , Christopher T. Winkelmann , Elaine Jagoda , Shailendra Patel , Gibson Imaging Apps, LLC, Holland, PA, 2 3 USA; Merck, Whitehouse Station, NJ, USA; NIH, Bethesda, MD, USA. Contact e-mail: raymond_gibson@comcast.net With the desire to develop novel drugs faster and more cost-effectively, drug companies are searching for clear strategies to manage the complex drug discovery process in terms of balancing costs, time, product value and possibility of success. To this end, pharmaceutical companies have turned to imaging, be it radiotracer imaging (PET and SPECT), magnetic resonance techniques (MRI, fMRI, and MRS), CT, ultrasound and optical imaging, as the means to determine the efficacy of drugs more quickly. Alternatively, imaging techniques may generate biomarkers that can demonstrate target engagement, important for the proof-of-principle studies the encourage further development of the putative drug entity. We have http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Molecular Imaging and Biology Springer Journals

Proceedings of the 2010 World Molecular Imaging Congress, Kyoto, Japan, September 8-11, 2010

1137 pages